Sickle cell disease-focused Modus Therapeutics AB has begun a Phase I dosing study in the US to assess the safety and tolerability of injecting the Swedish biotech’s lead asset sevuparin, the aim being to provide sickle cell patients with a non-opioid, therapy that can be dosed at home, rather intravenously in hospital, the group's CEO told Scrip.
The Phase I trial studying subcutaneously-administered sevuparin is being conducted in Florida in a hospital setting.